Mohammad Otahbachi, MD
Cardiovascular Disease · Lubbock, TXNPI 1184818353
Payments from drug & device makers
Across 379 payments — averaging $33.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Medtronic$2K
- Penumbra, Inc.$2K
- Abbott$1K
- Cardiovascular Systems Inc.$487
- Abiomed$336
- plus $3K from 31 others
What the payments were for
- Travel & lodging$3,00523%
- Food & beverage$9,85477%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 71 | $3,214 |
| Medtronic(2 entities) | 94 | $2,396 |
| Penumbra, Inc. | 10 | $2,035 |
| Abbott | 20 | $1,348 |
| Cardiovascular Systems Inc. | 15 | $487 |
| Abiomed | 8 | $336 |
| E.r. Squibb & Sons, L.L.C. | 20 | $332 |
| Shockwave Medical, Inc | 7 | $308 |
| Novartis | 15 | $306 |
| Pfizer | 17 | $291 |
| AstraZeneca | 11 | $276 |
| Merck | 16 | $245 |
| Johnson & Johnson | 19 | $239 |
| Stryker | 8 | $202 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $163 |
| Lilly USA, LLC | 1 | $118 |
| Novo Nordisk | 6 | $103 |
| Inspire Medical Systems, Inc. | 1 | $44 |
| Inari Medical, Inc. | 2 | $44 |
| Cardiva Medical, Inc. | 1 | $32 |
| GE HealthCare | 1 | $32 |
| Amgen | 2 | $30 |
| Scpharmaceuticals Inc. | 2 | $28 |
| Edwards Lifesciences | 2 | $27 |
| Cordis US CORP. | 1 | $26 |
| Amarin Pharma, Inc. | 2 | $25 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Avinger Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $17 |
| Smith+Nephew | 1 | $16 |
| Acacia Pharma Inc | 1 | $15 |
| Canon Medical Systems USA, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Surmodics, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$1,936
- VersaCross Access Solution$1,593
- Coronary Orbital Atherectomy System$226
- SYNERGY$215
- SYMPLICITY G3$186
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$165
- COREVALVE EVOLUT R$165
- ESPRIT$162
- Xience Sierra Coronary Stent System$134
- FARXIGA$122
- Resolute$119
- MOUNJARO$118
- GENERAL ULTRASOUND$117
- Impella$112
- Xience Sierra Coronary Stent$110
- Ultreon$107
- GENERAL VASCULAR INTERVENTION$103
- GUIDEZILLA$102
How this compares
$12,873 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 933 | $890,998 |
| EntrestoSacubitril/Valsartan | 236 | $292,565 |
| XareltoRivaroxaban | 136 | $118,609 |
| Repatha SureclickEvolocumab | 122 | $74,231 |
| BrilintaTicagrelor | 83 | $61,595 |
| VascepaIcosapent Ethyl | 92 | $61,045 |
| JardianceEmpagliflozin | 40 | $45,172 |
| Repatha SyringeEvolocumab | 38 | $30,711 |
| MultaqDronedarone Hcl | 23 | $29,322 |
| Praluent PenAlirocumab | 35 | $22,459 |
| Ranolazine ErRanolazine | 226 | $20,747 |
| FarxigaDapagliflozin Propanediol | 15 | $20,525 |
| EdarbiAzilsartan Medoxomil | 42 | $16,709 |
| Icosapent Ethyl | 44 | $13,940 |
| Atorvastatin Calcium | 1,273 | $10,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $291 | $890,998933 claims |
| NovartisEntresto | $306 | $292,565236 claims |
| Johnson & JohnsonXarelto | $239 | $118,609136 claims |
| AstraZenecaBrilinta, Farxiga | $276 | $82,12098 claims |
| Boehringer IngelheimJardiance | $17 | $45,17240 claims |
| Sanofi-aventis U.S. LLCMultaq | $13 | $29,32223 claims |
| MerckJanumet | $245 | $6,20311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Lubbock
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.